Philippine Society of Endocrinology, Diabetes and Metabolism

Also known as: PSEDM · Philippine Society of Endocrinology · PSEDM-Endocrine Society

Definition

The Philippine Society of Endocrinology, Diabetes and Metabolism (PSEDM) is the national professional specialty society of endocrinologists (specialists in endocrine disorders, diabetes, and metabolic diseases) in the Philippines. The PSEDM is the authoritative body for endocrinology specialty training accreditation, board certification (diplomate status), clinical practice guidelines, and continuing medical education in the Philippine setting. The Society works in coordination with the Philippine College of Physicians (PCP) as a recognized subspecialty component, and with the Food and Drug Administration (FDA) Philippines and the Department of Health (DOH) on diabetes and metabolic-disease public health policy. (Wikipedia — PSEDM)

Identities

Source Type	Identity
Wikipedia	Philippine Society of Endocrinology, Diabetes and Metabolism
Wikidata	N/A
DBpedia	N/A
ProductOntology	N/A
Wiktionary	N/A
Library of Congress Subject Headings (LCSH)	Endocrinology — Philippines / Diabetes — Philippines
MeSH	N/A
NCBI Taxonomy	N/A
AGROVOC	N/A
Google Scholar	“PSEDM” Philippines endocrinology diabetes guidelines
ConceptNet	N/A
OpenCyc	N/A

Also Known As

PSEDM
Philippine Society of Endocrinology
PSEDM-Endocrine Society

Examples and Analogies

National specialty-society analog: PSEDM is structurally analogous to the American Association of Clinical Endocrinologists (AACE) and the Endocrine Society (US) — a national specialty society of endocrinologists.

Usage Scenarios

1. Endocrinology Specialty Training Accreditation

PSEDM accredits endocrinology fellowship (subspecialty) training programs in Philippine teaching hospitals.

2. Clinical Practice Guidelines

PSEDM develops Philippine CPGs for Type 2 diabetes, thyroid disorders, osteoporosis, dyslipidemia, obesity management, and other endocrine-metabolic conditions.

3. GLP-1 Therapy Guidance

PSEDM has issued clinical guidance on GLP-1 receptor agonist prescribing in the Philippines — including semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda, Victoza).

4. Public Health Advocacy

Advocates for diabetes prevention, metabolic syndrome awareness, and rational pharmacotherapy — in coordination with DOH, PhilHealth, and PCP.

Strategies

Specialty training and diplomate certification authority
Clinical practice guideline development
Coordination with PCP, DOH, FDA Philippines, and PhilHealth
Public education on diabetes and metabolic disease

Security and Safety Measures

Diplomate certification ensures endocrinologist credentialing
CPGs inform safe clinical practice
Coordination with FDA on pharmacotherapy safety advisories

Historical Context

The PSEDM was established to consolidate Philippine endocrinology as a recognized subspecialty within Internal Medicine. The Society has been instrumental in developing Philippine diabetes management standards, including the adoption and dissemination of incretin-based therapy (GLP-1 receptor agonists, DPP-4 inhibitors) in Philippine clinical practice.

Challenges and Controversies

Workforce Distribution

Endocrinologists are concentrated in Metro Manila and major regional centers, limiting access in provincial areas.

GLP-1 Compounding Warnings

PSEDM has joined the FDA Philippines and PCP in issuing public warnings against compounded GLP-1 products.

PhilHealth Coverage Gaps

Advanced endocrine pharmacotherapy (GLP-1 receptor agonists, SGLT2 inhibitors) is largely not covered by PhilHealth, creating access disparities.

References

Wikipedia — Endocrinology (general reference)